Yttrium ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma: current status and future prospects.
After nearly three decades with little change in the treatment for B-cell non-Hodgkin's lymphoma, the addition of immunotherapy has had a profound effect on the treatment of this group of diseases. A more subtle addition to the armentarium has been the radiolabeled monoclonal antibodies, (90)yttrium ibritumomab tiuxetan and (131)iodine tositumomab. Unfortunately these drugs have been underutilized. This is, in part, because of the need for coordination between specialties, concern about long-term effects, possible limitations on the tolerance of subsequent therapies and, in part, because of reimbursement factors. In this review, the studies in relapsed and refractory disease are discussed and the very promising results reported from phase II studies using radioimmunotherapy as first-line. Potential mechanisms of resistance to monoclonal antibodies are postulated based on alterations in cell signaling pathways that have been observed in lymphoma cell lines resistant to rituximab. It is anticipated that as mechanisms of resistance are better understood for both unlabeled and labeled monoclonal antibodies, biomarkers will not only predict their efficacy but also lead to the development of therapies to overcome resistance.
Jacobs
Samuel A
SA
University of Pittsburgh School of Medicine, 5150 Centre Avenue, Pittsburgh, PA, USA.
Cancer Immunol Immunother. 2006 Dec;55(12):1451-8
16496145
Nature. 2000 Feb 3;403(6769):503-11
10676951
Clin Nucl Med. 2000 Nov;25(11):866-9
11079581
J Clin Oncol. 2006 Sep 20;24(27):4418-25
16940276
J Clin Oncol. 2007 Feb 10;25(5):579-86
17242396
J Biol Chem. 2005 Sep 2;280(35):31182-9
16000298
J Clin Oncol. 1998 Aug;16(8):2825-33
9704735
J Clin Oncol. 2003 Apr 1;21(7):1263-70
12663713
CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27
8548526
Blood. 2002 Jun 15;99(12):4336-42
12036859
Blood. 2000 Jun 15;95(12):3900-8
10845926
J Clin Oncol. 1999 Dec;17(12):3793-803
10577851
Ann Rheum Dis. 2007 Mar;66(3):351-7
16950808
J Clin Oncol. 2002 Aug 15;20(16):3545-57
12177115
Cancer Res. 2007 Feb 1;67(3):1335-43
17283171
J Clin Oncol. 2001 Oct 1;19(19):3918-28
11579112
Expert Rev Anticancer Ther. 2006 Jun;6(6):861-9
16761929
Cancer Res. 2004 Oct 1;64(19):7117-26
15466208
Mod Pathol. 2000 Feb;13(2):193-207
10697278
J Clin Oncol. 2003 Nov 1;21(21):3940-7
12975461
J Clin Invest. 2002 Jul;110(1):71-9
12093890
Clin Cancer Res. 2000 Feb;6(2):701-8
10690556
Science. 1993 Oct 29;262(5134):747-50
8235596
Cancer Immunol Immunother. 2003 May;52(5):309-16
12700946
J Clin Oncol. 2005 Aug 20;23(24):5696-704
16110029
N Engl J Med. 2005 Feb 3;352(5):441-9
15689582
Blood. 2002 Feb 1;99(3):754-8
11806974
Blood. 2004 Sep 1;104(5):1258-65
15126323
Blood. 2005 Oct 15;106(8):2896-902
16002426
Blood. 2004 Nov 1;104(9):2635-42
15226177
Ann Oncol. 1999 Jun;10(6):655-61
10442187
Blood. 2003 Oct 1;102(7):2351-7
12750161
Ann Oncol. 2001 Jan;12(1):109-14
11249036
Blood. 1994 Jan 15;83(2):435-45
7506951
Blood. 2000 Nov 1;96(9):2934-42
11049969
Blood. 2005 Jun 15;105(12):4576-82
15731177
Cancer. 2002 Feb 15;94(4 Suppl):1363-72
11877767
Clin Cancer Res. 2004 Dec 1;10(23):7792-8
15585610
Semin Nucl Med. 2002 Oct;32(4):293-321
12524653
Ann Hematol. 2005 Jan;84(1):1-12
15480663
J Clin Immunol. 2002 May;22(3):124-30
12078853
Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7146s-7150s
16203814
Blood. 1999 Oct 1;94(7):2217-24
10498591
J Clin Oncol. 2002 May 15;20(10):2453-63
12011122
Blood. 2007 Jul 1;110(1):54-8
17387223
Blood. 1997 Jul 1;90(1):244-51
9207459
Int J Oncol. 1999 Nov;15(5):1017-25
10536187
Clin Chest Med. 1990 Mar;11(1):65-71
2182279
Cancer Res. 2005 Jan 1;65(1):264-76
15665303
J Clin Oncol. 2002 Aug 1;20(15):3262-9
12149300
J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27
16204691
J Clin Oncol. 1995 Oct;13(10):2656-75
7595720
J Radiat Res. 2005 Jun;46(2):241-8
15988143
J Clin Oncol. 2000 Mar;18(6):1316-23
10715303
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1187-203
7713782
Cancer. 2006 Jul 15;107(2):433-8
16770786
Blood. 2004 Oct 15;104(8):2269-71
15166030
J Exp Med. 2002 Jun 17;195(12):1653-9
12070293
J Clin Oncol. 1999 Jun;17(6):1851-7
10561225
Blood. 2000 Aug 15;96(4):1259-66
10942366
J Exp Ther Oncol. 2004 Dec;4(4):305-16
15844660
J Clin Oncol. 2006 Sep 1;24(25):4143-9
16896003
J Immunol. 1985 Dec;135(6):3795-801
2415587
J Immunother. 2001 May-Jun;24(3):263-71
11394505
J Clin Oncol. 2007 Feb 10;25(5):571-8
17242397
J Clin Oncol. 2005 Jan 20;23(3):461-7
15534357
Blood. 2006 Sep 15;108(6):1975-8
16705086
J Clin Oncol. 2002 Sep 15;20(18):3885-90
12228209
Blood. 2001 Dec 1;98(12):3383-9
11719378
J Clin Oncol. 1998 Aug;16(8):2780-95
9704731
Cancer Res. 2007 Feb 1;67(3):1270-81
17283164
J Clin Oncol. 2012 Sep 1;30(25):3119-26
22851557